相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Syrbactin-class dual constitutive- and immuno-proteasome inhibitor TIR-199 impedes myeloma-mediated bone degeneration in vivo
Vasudha Tandon et al.
BIOSCIENCE REPORTS (2022)
Multiple Myeloma: Possible Cure from the Sea
Anita Capalbo et al.
CANCERS (2022)
From Nature to Synthetic Compounds: Novel 1(N),2,3 Trisubstituted-5-oxopyrrolidines Targeting Multiple Myeloma Cells
Roberta Listro et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Anti-Multiple Myeloma Potential of Secondary Metabolites from Hibiscus sabdariffa-Part 2
Alessio Malacrida et al.
MOLECULES (2021)
Natural products in drug discovery: advances and opportunities
Atanas G. Atanasov et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
The 20S as a stand-alone proteasome in cells can degrade the ubiquitin tag
Indrajit Sahu et al.
NATURE COMMUNICATIONS (2021)
The Landscape of Signaling Pathways and Proteasome Inhibitors Combinations in Multiple Myeloma
Tina Paradzik et al.
CANCERS (2021)
Modulation of the ubiquitin-proteasome system by marine natural products
Mary A. Vasilopoulou et al.
REDOX BIOLOGY (2021)
Genomic Instability in Multiple Myeloma: A Non-Coding RNA Perspective
Elisa Taiana et al.
CANCERS (2021)
Multiple Myeloma Inhibitory Activity of Plant Natural Products
Karin Joehrer et al.
CANCERS (2021)
Impact of Natural Dietary Agents on Multiple Myeloma Prevention and Treatment: Molecular Insights and Potential for Clinical Translation
Lavinia Raimondi et al.
CURRENT MEDICINAL CHEMISTRY (2020)
Proteasome Inhibitor Drugs
Lloyd D. Fricker
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 60 (2020)
Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo
Marquicia R. Pierce et al.
LEUKEMIA RESEARCH (2020)
The proteasome 19S cap and its ubiquitin receptors provide a versatile recognition platform for substrates
Kirby Martinez-Fonts et al.
NATURE COMMUNICATIONS (2020)
The Non-Coding RNA Landscape of Plasma Cell Dyscrasias
Eugenio Morelli et al.
CANCERS (2020)
Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019
David J. Newman et al.
JOURNAL OF NATURAL PRODUCTS (2020)
Non-Coding RNAs in Multiple Myeloma Bone Disease Pathophysiology
Lavinia Raimondi et al.
NON-CODING RNA (2020)
Celastrol induce apoptosis of human multiple myeloma cells involving inhibition of proteasome activity
Yue-ling Zhong et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2019)
A Practical Review of Proteasome Pharmacology
Tiffany A. Thibaudeau et al.
PHARMACOLOGICAL REVIEWS (2019)
Discovery of Natural Proteasome Inhibitors as Novel Anticancer Therapeutics: Current Status and Perspectives
Hui Wang et al.
CURRENT PROTEIN & PEPTIDE SCIENCE (2018)
Plant Secondary Metabolites as Anticancer Agents: Successes in Clinical Trials and Therapeutic Application
Ana M. L. Seca et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Proteasome inhibitors for multiple myeloma
Kiyoshi Okazuka et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2018)
Regulation of proteasome assembly and activity in health and disease
Adrien Rousseau et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2018)
Characterization of naturally occurring pentacyclic triterpenes as novel inhibitors of deubiquitinating protease USP7 with anticancer activity in vitro
Bo Jing et al.
ACTA PHARMACOLOGICA SINICA (2018)
Epigenetic modifications in multiple myeloma: recent advances on the role of DNA and histone methylation
Nicola Amodio et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2017)
Genomic complexity of multiple myeloma and its clinical implications
Salomon Manier et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Prodrugs of triterpenoids and their derivatives
Meng Zhou et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Tyropeptins, proteasome inhibitors produced by Kitasatospora sp MK993-dF2
Isao Momose et al.
JOURNAL OF ANTIBIOTICS (2017)
Proteasome Structure and Assembly
Lauren Budenholzer et al.
JOURNAL OF MOLECULAR BIOLOGY (2017)
Proteasome inhibitors in cancer therapy
Elisabet E. Manasanch et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Structural insights into the functional cycle of the ATPase module of the 26S proteasome
Marc Wehmer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Multiple myeloma
Shaji K. Kumar et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
The proteasome and proteasome inhibitors in multiple myeloma
Sara Gandolfi et al.
CANCER AND METASTASIS REVIEWS (2017)
Pristimerin inhibits proliferation, migration and invasion, and induces apoptosis in HCT-116 colorectal cancer cells
Bashir A. Yousef et al.
BIOMEDICINE & PHARMACOTHERAPY (2016)
Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1
P. G. Richardson et al.
BLOOD (2016)
Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients
Nancy Levin et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Syrbactin Structural Analog TIR-199 Blocks Proteasome Activity and Induces Tumor Cell Death
Andre S. Bachmann et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Natural Products as Sources of New Drugs from 1981 to 2014
David J. Newman et al.
JOURNAL OF NATURAL PRODUCTS (2016)
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar et al.
LANCET ONCOLOGY (2016)
Computational Approaches for the Discovery of Human Proteasome Inhibitors: An Overview
Romina A. Guedes et al.
MOLECULES (2016)
The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design
Jil Schrader et al.
SCIENCE (2016)
MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment
Lavinia Raimondi et al.
BIOMED RESEARCH INTERNATIONAL (2016)
DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma
Nicola Amodio et al.
Oncotarget (2015)
Antitumor effects of tyropeptin-boronic acid derivatives: New proteasome inhibitors
Isao Momose et al.
CANCER SCIENCE (2014)
BCR-ABL disrupts PTEN nuclear-cytoplasmic shuttling through phosphorylation-dependent activation of HAUSP
A. Morotti et al.
LEUKEMIA (2014)
Mechanisms and consequences of constitutive NF-κB activation in B-cell lymphoid malignancies
D. Nagel et al.
ONCOGENE (2014)
Ursolic acid in cancer prevention and treatment: Molecular targets, pharmacokinetics and clinical studies
Muthu K. Shanmugam et al.
BIOCHEMICAL PHARMACOLOGY (2013)
miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells
Nicola Amodio et al.
CELL CYCLE (2013)
U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma
Thomas M. Herndon et al.
CLINICAL CANCER RESEARCH (2013)
Non-coding RNA: a novel opportunity for the personalized treatment of multiple myeloma
Nicola Amodio et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2013)
USP1 deubiquitinase: cellular functions, regulatory mechanisms and emerging potential as target in cancer therapy
Iraia Garcia-Santisteban et al.
MOLECULAR CANCER (2013)
The proteasome and the degradation of oxidized proteins: Part I-structure of proteasomes
Tobias Jung et al.
REDOX BIOLOGY (2013)
Proteasome inhibitors in multiple myeloma: 10 years later
Philippe Moreau et al.
BLOOD (2012)
A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib Resistance
Dharminder Chauhan et al.
CANCER CELL (2012)
Selective Dual Inhibitors of the Cancer-Related Deubiquitylating Proteases USP7 and USP47
Joseph Weinstock et al.
ACS MEDICINAL CHEMISTRY LETTERS (2012)
Synthetic Oleanane Triterpenoids: Multifunctional Drugs with a Broad Range of Applications for Prevention and Treatment of Chronic Disease
Karen T. Liby et al.
PHARMACOLOGICAL REVIEWS (2012)
Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
D. Chen et al.
CURRENT CANCER DRUG TARGETS (2011)
Natural products: An evolving role in future drug discovery
Bhuwan B. Mishra et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2011)
Proteasome inhibitors in cancer therapy
Lisa J. Crawford et al.
JOURNAL OF CELL COMMUNICATION AND SIGNALING (2011)
Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-κB signaling and depleting Bcr-Abl
Zhongzheng Lu et al.
MOLECULAR CANCER (2010)
Inhibition of the Ubiquitin-Proteasome System by Natural Products for Cancer Therapy
Sachiko Tsukamoto et al.
PLANTA MEDICA (2010)
3-Oxo-11β-hydroxyfriedelane from the roots of Celastrus monospermus
Ming-Xiang Chen et al.
JOURNAL OF CHEMICAL RESEARCH (2010)
Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-κB with antimyeloma activity in vitro and in vivo
Rodger E. Tiedemann et al.
BLOOD (2009)
Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors
Encouse B. Golden et al.
BLOOD (2009)
Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells
Frederic Colland et al.
MOLECULAR CANCER THERAPEUTICS (2009)
The proteasome: Overview of structure and functions
Keiji Tanaka
PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES (2009)
A plant pathogen virulence factor inhibits the eukaryotic proteasome by a novel mechanism
Michael Groll et al.
NATURE (2008)
Pristimerin induces apoptosis by targeting the proteasome in prostate cancer cells
Huanjie Yang et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2008)
Roselle (Hibiscus sabdariffa) seed oil is a rich source of γ-tocopherol
R. Mohamed et al.
JOURNAL OF FOOD SCIENCE (2007)
Ursolic acid inhibits STAT3 activation pathway leading to suppression of proliferation and chemosensitization of human multiple myeloma cells (Publication with Expression of Concern. See vol. 16, pg. 1442, 2018)
Ashutosh K. Pathak et al.
MOLECULAR CANCER RESEARCH (2007)
Induction of apoptosis in human leukemia cells by black tea and its polyphenol theaflavin
T Kundu et al.
CANCER LETTERS (2005)
Pristimerin induces caspase-dependent apoptosis in MDA-MB-231 cells via direct effects on mitochondria
CC Wu et al.
MOLECULAR CANCER THERAPEUTICS (2005)
The evolving role of natural products in drug discovery
FE Koehn et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
Functional analysis of genes involved in the synthesis of syringolin A by Pseudomonas syringae pv. syringae B301D-R
H Amrein et al.
MOLECULAR PLANT-MICROBE INTERACTIONS (2004)
The function of the protein tyrosine phosphatase SHP-1 in cancer
CY Wu et al.
GENE (2003)
The proteasome: a novel target for cancer chemotherapy
JB Almond et al.
LEUKEMIA (2002)
Tyropeptins A and B, new proteasome inhibitors produced by Kitasatospora sp MK993-dF2 -: II.: Structure determination and synthesis
I Momose et al.
JOURNAL OF ANTIBIOTICS (2001)
Tyropeptins A and B, new proteasome inhibitors produced by Kitasatospora sp MK993-dF2 -: I.: Taxonomy, isolation, physico-chemical properties and biological activities
S Momose et al.
JOURNAL OF ANTIBIOTICS (2001)
The axial channel of the proteasome core particle is gated by the Rpt2 ATPase and controls both substrate entry and product release
A Köhler et al.
MOLECULAR CELL (2001)
分享论文
